Bryan Faust, PhD
San Francisco, California, United States
3K followers
500+ connections
Activity
-
One of the nicest parts of today’s launch was reading this beautiful piece from Vineeta Agarwala, MD PhD and Bryan Faust, PhD at a16z Bio + Health…
One of the nicest parts of today’s launch was reading this beautiful piece from Vineeta Agarwala, MD PhD and Bryan Faust, PhD at a16z Bio + Health…
Liked by Bryan Faust, PhD
-
I am so proud to be a part of the Stipple team and extremely excited for what is to come!
I am so proud to be a part of the Stipple team and extremely excited for what is to come!
Liked by Bryan Faust, PhD
-
https://lnkd.in/eN-5J54f I’m very proud to be a part of the Stipple Team and extremely excited for what’s to come!
https://lnkd.in/eN-5J54f I’m very proud to be a part of the Stipple Team and extremely excited for what’s to come!
Liked by Bryan Faust, PhD
Experience
Education
-
University of California, San Francisco
-
Thesis: Antibody control of protein conformation in pathology and for therapeutic pharmacology
-
-
Publications
-
Autoantibody mimicry of hormone action at the thyrotropin receptor
Nature
See publicationBiophysical characterization (cryo-EM and all-atom molecular dynamics) and pharmacological interrogation of hormone and autoantibody mediated conformational control at the human Thyrotropin receptor.
-
Selective G protein signaling driven by substance P–neurokinin receptor dynamics
Nature Chemical Biology
See publicationCryo-EM, molecular dynamics, and in vitro signaling experiments reveal the importance of the full complement of neuropeptide contacts at the Neurokinin receptor (NK1R) for balanced G protein signaling. Disruption of neuropeptide:extracellular loop contacts diminishes Gs, but not Gq, activation by NK1R.
-
Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia
Cell
See publicationBiophysical characterization of SARS-CoV-2 neutralizing antibodies that not only block Spike-mediated viral entry but also modulate Spike-mediated syncytia formation.
-
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
Science
See publicationDiscovery, characterization, and structure guided engineering of single-domain antibodies capable of eliciting conformational control of SARS-CoV-2 Spike proteins as a means to elicit passive immunity against COVID-19.
-
Lipid Nanodiscs via Ordered Copolymers
Chem - CellPress
See publicationDevelopment of amphipathic co-polymers for improved extraction and solubilization of membrane proteins in "native" nanodiscs.
-
Robust Sequence Determinants of α-Synuclein Toxicity in Yeast Implicate Membrane Binding
ACS Chemical Biology
See publicationDeep mutational scanning to investigate how a toxic conformation of α-synuclein, a dynamic protein linked to Parkinson’s disease, responds to perturbations of cellular proteostasis.
-
Smoothened stimulation by membrane sterols drives Hedgehog pathway activity
Nature
See publicationProposes a model for activation of Smoothened, a class F GPCR implicated in embryonic development, via sterol occupancy in the orthosteric binding site.
Languages
-
Spanish
-
More activity by Bryan
-
Infinimmune is just 44 months old. Today we announced an $838MM discovery partnership with Merck, one of the world's best drug developers. This deal…
Infinimmune is just 44 months old. Today we announced an $838MM discovery partnership with Merck, one of the world's best drug developers. This deal…
Liked by Bryan Faust, PhD
-
Today, along with our partner Hengrui Pharma, we're pleased to share positive Phase 2 results for HRS/BHB-1893 in obstructive hypertrophic…
Today, along with our partner Hengrui Pharma, we're pleased to share positive Phase 2 results for HRS/BHB-1893 in obstructive hypertrophic…
Liked by Bryan Faust, PhD
-
After two years of heads-down development, it is time to lift the veil on Antelope Therapeutics. Since 2024, we have been working in stealth mode…
After two years of heads-down development, it is time to lift the veil on Antelope Therapeutics. Since 2024, we have been working in stealth mode…
Liked by Bryan Faust, PhD
-
We are pleased to announce positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor…
We are pleased to announce positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor…
Liked by Bryan Faust, PhD
-
I’m thrilled to share that I’ve officially joined CREATE Medicines as Senior Vice President, Autoimmune Clinical Development. I’m incredibly…
I’m thrilled to share that I’ve officially joined CREATE Medicines as Senior Vice President, Autoimmune Clinical Development. I’m incredibly…
Liked by Bryan Faust, PhD
-
It began with a brilliant biological insight from Jaideep Dudani and a trip to Chengdu to meet the gracious team at Keymed Biosciences - and has…
It began with a brilliant biological insight from Jaideep Dudani and a trip to Chengdu to meet the gracious team at Keymed Biosciences - and has…
Liked by Bryan Faust, PhD
-
When we launched in January 2025, we set out to redefine the standard of care for patients with chronic immune-mediated diseases through immune reset…
When we launched in January 2025, we set out to redefine the standard of care for patients with chronic immune-mediated diseases through immune reset…
Liked by Bryan Faust, PhD
-
Today, Ouro Medicines entered into a definitive agreement to be acquired by Gilead Sciences for up to $2.175B. It has been a privilege to serve on…
Today, Ouro Medicines entered into a definitive agreement to be acquired by Gilead Sciences for up to $2.175B. It has been a privilege to serve on…
Liked by Bryan Faust, PhD
Other similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content